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Molecular genetic identification of families with juvenile nephronoph-
thisis type 1: Rate of progression to renal failure. Familial juvenile
nephronophthisis (NPH), an autosomal recessive cystic disease of the
kidney, is the most common genetic cause of end-stage renal disease
(ESRD) in the first two decades of life. A gene locus for nephronophthisis
type I (NPH1) has been mapped by linkage analysis to chromosome 2q13.
We performed a haplotype analysis in 16 NPH families with at least two
affected patients with the typical history, clinical signs and histology of
NPH using microsatellite markers of the NPH1 genetic region. By
demonstration of a recombinant event marker D2S 1893 was identified as
a novel centromeric flanking marker to the NPH1 critical genetic region.
Absence of linkage to the NPH1 locus in six NPH families confirmed the
existence of at least one additional gene locus for NPH. Linkage to the
NPH1 locus was demonstrated in 10 families. In 8 of these families a
homozygous deletion was identified. These data permit for the first time
the study of the development of renal failure in a subset of NPH1 families,
which is most likely homogeneous with regard to the responsible gene
locus. We present a statistical description of serial serum creatinine
measurements in NPHI. Analysis of renal death revealed a median of 13.1
years. Age-dependent quartiles were generated for serum creatinine. In
summary, the new marker provides a diagnostic tool to aid in the diagnosis
of NPH, while the progression charts offer a standard for an assessment of
the rate of progression to ESRD for patients with NPHI to be used in
future therapeutic trials and for a prediction of the individual course of the
disease.
Familial juvenile nephronophthisis (NPH) is an autosomal
recessive tubulointerstitial kidney disease [1, 2] leading to termi-
nal renal failure during adolescence [3]. NPH represents the most
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common genetic cause for end-stage renal disease in childhood
[4]. NPH has been described to account for 14% [5] and for 10%
[3] of all children with chronic renal failure. Initial symptoms of
polyuria and polydipsia may start at around age six years, followed
by the development of anemia and growth retardation. Due to
renal salt loss, edema and hypertension are rare, even in advanced
stages of the disease. Therefore, the disease in many cases is
diagnosed late in the course of renal failure, when children may
present acutely with an episode of severe dehydration [6].
Extrarenal organ involvement is well known in recessive NPH
including mainly retinitis pigmentosa [7, 8], liver fibrosis [91,
cone-shaped epiphyses [10] and aplasia of the cerebellar vermis
[11]. An autosomal dominant form of the disease, which is
indistinguishable from recessive NPH on histologic grounds has
been described [12]. This disease entity differs from NPH by its
mode of inheritance, its clinical course with development of
ESRD only in the third decade of life, and the lack of extrarenal
associations. The autosomal dominant form should be termed
"medullary cystic disease of the kidney" to discriminate this
genetic entity from recessive NPH [13].
Renal histology in early stages reveals peritubular lymphohis-
tiocytic infiltrations with consecutive development of a chronic
sclerosing tubulointerstitial nephropathy with tubular atrophy and
dilation. Cysts occur primarily at the corticomedullary junction of
the kidneys. Light microscopy and electron microscopy reveal
thickening, splitting and attenuation of the tubular basement
membrane (TBM) [31.
A defect of tubular basement membrane composition has
previously been suggested as the primary genetic defect in NPH
[14]. More recently, abnormal expression of the aS integrin
fibronectin receptor was demonstrated by immunoperoxidase
stain in the tubular basement membrane of patients with NPH
[15]. This lead to the hypothesis that renal tubular cells in NPH
express a5 integrin fibronectin receptor as a compensatory mech-
anism for defective function of the a6 integrin molecule. This in
turn might lead to destruction of the TBM, which is a typical
histologic finding early in the course of NPH.
Linkage analysis lead to the mapping of the NPHI locus to
chromosome 2 [16, 17]. Consecutively, we have defined a critical
interval of 15 cM between markers at loci D2S135 and D2SIIO as
containing the NPHI gene by haplotype analysis in a large family.
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The region maps cytogenetically to 2q12-(2q13 or adjacent bands)
[17, 181. Medhioub et a! [191 used haplotype analysis of small
families to localize the NPHI gene to within an even closer
interval of 5 to 7 cM, between D2S293/D2S340 and D2S121 on
chromosome 2q13. This assignment was Consistent with mapping
of NPHI to 2q11.1-q2i.1, based on haplotype data in a large
family, and the identification of D2S293 and D2S363 as flanking
markers within an 8 cM interval in 12 small families [201. The
NPH1 genetic region has recently been cloned in complete contigs
of yeast artificial chromosome (YAC) clones as a means to
identifying the gene responsible for NPH1 [21, 22]. We recently
defined marker AFMO4I xci as a telomeric flanking marker to the
NPHI genetic region by detection of a recombinant event in an
NPH1 family (Hildebrandt et al, unpublished observation).
D2S160 has been defined as an additional telomeric flanking
marker by homozygosity mapping [23]. The minimum genetic
region for NPH1 (measuring approximately 3 Mb) is therefore
defined by flanking markers D2S340 and AFMO41xcI on the
centromeric and telomeric sides, respectively. Most recently,
marker D2S 1888 was identified as the narrowest telomeric flank-
ing marker [211. In this report we define by haplotype analysis
marker D2S1893 as a novel, narrow centromeric flanking marker
to NPH1, thereby confining the critical region to approximately 1
Mb. Recently, the presence of large homozygous deletions of the
NPHI critical region was described in 80% of inbred or multiplex
NPHI families [24]. Genetic locus heterogeneity was suggested by
the fact that about 17% of NPH families with at least two affected
patients showed a lack of linkage to the NPHI genetic region. The
presence of a subset of families unlinked to NPH1 is confirmed in
the present report.
In the present report we used haplotype analysis to detect
linkage to NPI-l1. In addition, a newly identified genetic marker
Al 1 2
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Fig. 1. Haplotypes of 16 families with NPJ-1 using microsatellite markers of the NPH1 genetic region on chromosome 2q13. Squares represent males, circles
represent females. Filled symbols indicate individuals affected by NPH. Above the symbols families and individuals of both generations are numbered.
Microsatellite loci are given in the first column. Allele coding is used as published (Methods). In the children paternal haplotypes are represented in
the left column, maternal haplotypes are represented in the right column. The paternal and maternal haplotypes that are associated with the affected
status are shown white on black, while the haplotypes associated with the normal allele are shown black on white. Markers with uninformative meloses
(homozygous in a parent) are represented in the children on a grey background. Markers detecting a recombination are underlined. Alleles were
downcoded for better readability. A. (above and continued opposite) A recombinant event in family 8 11-3 defines D2S1893 as a novel closest proximal
flanking marker to the NPH1 genetic region. In 10 NPH families there is full cosegregation of the affected status with the haplotypes assumed to be
associated with the mutant NPHI allele (black) within the flanking markers D2S1893 and AFMO41xc1, indicating linkage of these families to NPH1.
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Fig. 1A, part 2
(9657T) was used as a non-invasive diagnostic test to screcn 16
multiplex NPH families for the presence of a deletion in the
critical NPH1 genetic region. Of ten NPH families in which the
haplotypes were compatible with linkage to NPHI, 8 families were
positively diagnosed as NPHI by demonstration of the presence of
a deletion for 9657T.
The aim of this study was to define by haplotype analysis and trials.
deletion detection a group of NPH1 patients who show an absence
of genetic locus heterogeneity, and to examine the rate of
progression to renal failure within this homogeneous subset of
patients with NPH1. These data will allow a prediction for the rate
of progression to renal failure for patients with NPHI, and
provides a basis for the evaluation of potential future therapeutic
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Fig. lB. In six NPH families there is no linkage to NPH1.
Methods D2S283, D2S 110, and D2S343. Microsatdilites GATAp34277 and
GAATp3333O were from the Whitehead/MIT Center for Gcnome
Haplotype analysis Research f28]. Markers D2S1893 and AFMO41xc1 were from the
Gcnoniic DNA was isolated by standard methods [251 directly 1996 Genethon rnicrosatellite map [29]. The marker at the
from blood samples or after EBV transformation of peripheral interleukin I-a locus (ILl A) was obtained from the Genome I)ata
blood lymphocytes [26]. Highly polymorphic microsatellite mark- Base [30]. Marker LA2C was kindly contributed by M. MeAlcer
crs that localize to chromosome 2q were examined by PCR (McAleer, 1993, personal communication).
amplification followed by polyacrylamide gel clectrophoresis and A human genomic P1-related artificial chromosome (PAC)
autoradiography. clone (Genome Systems, St. Louis, MO, USA) was localized to
Microsatellite markers of the following loci were from the the NPH1 critical region by STS content mapping (Hildehrandt et
second generation linkage map of the Genethon [271: D2S135, al, unpublished data) and sequenced from the T7-end by a rapid
D2S176, D2S293, D2S340, D2S160, D2S121, D2S308, D2S363, cycle sequencing method according to the ThermoSequenase
S e
FlO F8
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Age, years
Fig. 3. Renal survival in 19 patients of 8 flimilies with NPHI as proven by
deletion detection. The start of renal replacement therapy, death due to
uremia or the occurrence of a serum creatinine > 5.5 mgldl was defined as
"renal death." Four patients were regarded as censored (vertical strokes
but no drop in survival curve) since renal death did not occur during the
observation period. The "median survival time" was 13.1 years. A testing
for gender difference in renal survival could not be done due to the small
sample size.
protocol (Amersham USB, Gaithersburg, PA, USA). Primers ftr
polymerase chain reaction (PCR) for marker 9657T were derived
from the sequence obtained (primer 9657Ta 5'-TCYFCACG-
GAGGAGCAcAGTC-3', primer 9657Th 5'-CCCAACTTTG-
CAAGCAGAAG-3'). Oligonucleotides were synthesized with an
Applied Biosystems model 392 DNA/RNA synthesizer. This
marker was identified as homozygously deleted in NPH1 patients.
It is localized between markers D2S340 and AFM041xcI (Fig. 1).
PCR was performed with dry template of 10 to 30 ng of genomie
DNA, 6 to 18 pmol of primers, 0.2 mivi each of dATP, dGTP,
dTTP, 2.5 jrM dCTP, 0.1 jiCi/j.d 32P-udCTP, 10 mivi Tris-HC1
(pH7.3), 50 mrvi KCI, 0.001% gelatin (wt/vol) and 0.3 U of
Thermus aquaticus DNA polymerase (Perkin Elmer Cetus, Uber-
Fig. 2. Detection of a homozygous deletion for
marker 9657T in the NPH] critical genetic region.
Affected individuals are shown as filled symbols
and non-affected individuals as empty symbols.
Polymorphic microsatellite marker D2S 1893
that lies outside the deleted region is used as a
positive control. The position of the 260 bp
allele is indicated as well as the expected PCR
product size of 211 bp of deletion marker
9657T. In family FlO none of the affected
children exhibits a deletion of marker 9657T.
This family is shown as representative for six
families not linked to NPH1 and exhibiting no
deletion for 9657T. Family F8 is shown as
representative for eight families exhibiting a
homozygous deletion for marker 9657T in the
affected children (see text). The parents arc
heterozygous and the non-affected siblings are
heterozygous and therefore produce a PCR
product for 9657T.
lingen, Germany). After the initial denaturation at 94°C for four
minutes, 32 cycles were performed at 94°C for 30 seconds, 55°C
for 40 seconds, and 72°C for 40 seconds, followed by a six minute
final extension step at 72°C. The amplified fragments were
separated by electrophoresis in 8% denaturing polyacrylamide
sequencing gels. The gels were blotted Onto Whatman paper,
dried, and autoradiography was performed for 2 to 16 hours.
Where possible, markers were examined in a multiplex PCR
method. Results were interpreted independently by two investi-
gators.
Patients
Blood samples and pedigrees were obtained following informed
consent from 16 multiplex families with NPH from central Europe
and the United States (39 affected and 18 unaffected siblings). The
diagnosis of NPH was made by a nephrologist. Diagnostic criteria
were the development of end-stage renal disease, following a
typical history of NPH with polyuria, polydipsia, anemia, and
growth retardation. In all NPH families but one (family 8) the
diagnosis was confirmed by renal biopsy. In the family where no
biopsy was performed, clinically there was no doubt with regards
to the accuracy of the diagnosis. Only multiplex families, that is,
families with at least two affected patients, were included in the
study. Unaffected siblings were included in the study only if they
had reached 14 years of age with no clinical evidence of NPH.
There was no known consanguinity in these families, and neither
was there extrarenal involvement in any of the patients included in
the study. Some of these families have been partially reported
previously [201. Serial determinations of 308 values for serum
creatininc were asscrtained retrospectively.
Statistical analysis
For the data evaluation the Statistical Analysis System (SAS)
was used. The following procedures were applied: LIFETEST for
survival analysis [311, TTEST for performing a f-test [31], UNT-
VARIATE for the calculation of median values [32], and GPLOT
for the graphical presentation of the data [33]. Data on mean
progression of renal failure were obtained by using the same
approach as published previously [34—36].
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Results
liaplotype analysis
We performed haplotype analysis in sixteen families with at
least two affected patients exhibiting the typical history, clinical
signs and histology (with the exception of family 8) of NPlt In
these families 39 children were affected and 18 were unaffected.
All parents except one mother (family 29) were available for
study. In the children only one affected and one unaffected child
was not available for study (F22 11-3 and F25 11-2). Altogether,
seventeen polymorphic microsatellite probes to the NPFII genetic
region were employed in the haplotype analysis. The results are
shown in Figure 1 A and B. In family 8, marker D2S1893 is shown
in addition and detected a novel recombinant event and therefore
was identified as the new centromerie flanking marker closest to
the critical genetic region of NH-Il (Fig. IA; F8 11-3).
0 5 10 15 20 25
Age (years) at serum creatinine 5.5 mg/dl
Fig. 5. Age at an S,. value of 5.5 mg/c/Iin (A) NPHI families (N = 8), and
(B) non-NPHJ families (N = 7). Members of the same family are
connected with a horizontal line. Symbols in parentheses represent age
values extrapolated from 5Cr slopes in individuals that have not yet
reached an Scr of 5.5 mgldl.
In 10 NPH families there was full cosegregation of the affected
status with the haplotypes associated with the mutant NPH1 allele
within the NPHI critical genetic region flanked by markers
D2S1893 and AFMO41xcI (Fig. IA). This finding indicates link-
age of these families to NPHI. All recombinations observed lay
outside this NPHI minimum genetic region. For example, note in
family 19, offspring 2, who exhibited a recombinant event that had
occurred in the maternal meiosis between locus D2S293 and
marker GATAp34277 (Fig. IA; F19 11-2). In contrast to the
finding in these 10 families there was no linkage to NPHI in 6
NPH families (Fig. 1B). For example, see affected offspring 2 in
family 30, who inherited the maternal haplotype (white), which
does not cosegregate to the other two affected siblings (Fig. IB;
F30). These data confirm the existence of at least one additional
gene locus for NPH.
Haplotype data were corroborated by molecular genetic anal-
ysis in all 16 NPH families with marker 9657T detecting a
homozygous deletion in NPH1 patients. Marker D2S1893, which
is known not to be deleted in NPHI, was used as a positive
control. As expected, there was no deletion detected in any of the
six families (Fig. I B) exhibiting an absence of linkage to N PHI. As
an example, the data for family 10 are shown in Figure 2.
However, in all affected children in 8 of the 10 families exhibiting
linkage to NPH1 by haplotype analysis (Fig. IA) a deletion of
9657T was detected. As an example the data for family 8 are
shown in Figure 2. No deletion was found in any of the affected
children of linked families 12 and 24 (data not shown). The
absence of a deletion for 9657T in 2 Out of 10 families with linkage
to NPHI does not come as a surprise, since haplotype analysis in
small families is suggestive of linkage but cannot be taken as proof
of linkage as long as the respective lod score in a candidate region
A
10
B —4
a a
I.) •
F32
F30
Fl 0
F92
F24
Fl 2
F86
F20
F8
F25
F19
F22
A
0 5 10 15 20
B
U —
..
—
a a
Standardized age, years
F29
F9
F2 1
.. a
0
0 5 10 15 20
Standardized age, years
Fig. 4. Progression chart representing the average course of deterioration of
renal function in patients suffering from NPHI. (A) Median (solid line) and
quartile (dashed lines) curves calculated from 308 serial values and (B)
after application of a spline function [331.
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is not higher than 2 [37], which would require a family size of
family 22 (Fig. 1A). Hence, linkage in small recessive families
might well be fortuitous. However, the detection of a deletion in
these 8 families clearly defines on a molecular genetic basis a
subset of NPHI families with no genetic locus heterogeneity. This
homogeneous subset was therefore used for assessment of the
rate of progression to renal failure.
Development of ESRD in NPHJ families
Median age at renal death, defined as serum creatinine contin-
uously> 5,5 mgldl, was 13.1 years (quartiles are: 75%, 17.3 years;
25%, 11.3 years) with a total of 4 patients (21%) being censored.
The resulting survival curve exhibited no major plateau formation
in the middle part, but towards the end indicated a homogenous
occurrence of renal death (Fig. 3). The median observation period
in the 19 patients was 40 months (range 1 to 129 months). During
this observation period a total of 308 serum creatinine determi-
nations (Scr) were obtained. The median number of SCr values
per patient was 14 (range I to 50). In 12 patients an S of 5 mgldl
was reached within a narrow time frame of 11.1 to 18.2 years of
age.
From the longitudinal Se,. values the median progression rate
according to age was calculated as described previously [341. In
the first step the data were divided into Scr intervals of 1 unit.
Then the median age was determined when the individual patient
had permanently reached this serum creatinine interval. Thereaf-
ter median values of all patients for a given interval were
calculated and plotted. The median and quartile curves (Fig. 4A)
constructed in this way were smoothed by using a spline function
(Fig. 4B) [33]. The analyzed individual serum creatinine values
demonstrate a continuous loss of renal function, as indicated by
the nearly constant distance between median and quartile curves.
The loss is relatively constant with little variation. None of the
parameters examined for Sr time course changed significantly
after inclusion of the data of the five affected children from
families 12 and 24, which showed linkage to NPH1 in the absence
of a deletion (data not shown).
We analyzed the intrafamilial variability of the course of the
disease. For this purpose the time when an value of 5.5 mg/dl
was reached was plotted (Fig. 5). In addition, the difference
between the most progressive member of a family and all other
members was assessed, and if possible a mean difference was
calculated. These data revealed no significant difference (P
0.5 111) with respect to intrafamilial variability between the group
of patients bearing a deletion (NPH1) (6.1 5.9 years) and the
patients without the deletion (non-NPH1) (4.3 2.6 years). The
interfamilial difference between families hearing the deletion and
families with absence of the deletion was assessed by computing
the age at which an SCR value of 5.5 mg/dl was reached in the
family member with most rapid progression to end-stage renal
disease (Fig. 5). These values were 10.5 3.2 years in the group
with the presence of the deletion versus 13.1 3.5 years in the
group with an absence of the deletion. There was no significant
difference by f-test (P = 0.1541) between both groups. Likewise, if
the mean age at S 5.5 mgldl was determined for each family
there was no significant difference found in families exhibiting a
deletion of marker 9657T (NPH1 families, 13.8 3.3 years) and
families without the deletion (non-NPHI families, 15.4 3.4
years; P = 0.3566).
Discussion
A major problem in the management of patients with suspected
juvenile nephronophthisis is the difficulty of firmly establishing the
correct diagnosis. In this study a non-invasive diagnostic test
requiring only a blood sample is described, which provides a tool
for establishing or confirming the diagnosis of NPH1. With the
help of this test the notorious problem of establishing the correct
diagnosis can be relieved at least for the cases with deletion-
positive NPH1, which constitute up to 85% of all NPH patients
[24].
A second major problem in the clinical course of NPH rests in
the fact that the period of terminal renal failure falls into puberty
and its preceeding years. In this age group sequelae of renal
failure interfere severely with growth and psychosocial develop-
ment. The present study addresses the need for the ability to give
a prognosis regarding the estimated time course of deterioration
of renal function. A statistical description of progression towards
renal failure in a homogeneous subset of NPH1 families as
defined by molecular genetic criteria has thus far been lacking.
Since molecular genetic criteria allowed the definition of a subset
of NPH1 families, for the first time it was possible to study the
development of renal failure in NPH1 families who are most likely
homogeneous with regards to the responsible gene locus. We,
therefore, generated an age-dependent course (median and quar-
tile curves of Sr values), thus providing a standard for assessing
the rate of progression to ESRD in this well defined subgroup of
NPHI families.
In two of the 10 families compatible with linkage to NPHI by
haplotype analysis no deletion of marker 9657T was found.
Haplotype analysis in small families is suggestive of linkage but
cannot be taken as proof of linkage as long as the respective lod
score in a candidate region is not higher than 2 [371. Therefore,
the absence of a deletion for marker 9657T in 2 out of 10 linked
NPH1 families might be fortuitous or, alternatively, a smaller
deletion or point mutation might be responsible for NPHI in
these two families. Since there is evidence that the extent of the
deletions seems not to be identical in all NPH1 patients [241, the
presence of a deletion of 9657T confirms the diagnosis of NPHI;
its absence, however, does not exclude the presence of a smaller
deletion in the NPH1 region. The ratio of 8 out of 10 families
linked to NPHJ bearing a homozygous deletion of the NPHI
region is in full accordance with the ratio described previously
[24]. So far we were unable to detect any clinical differences
between patients from families bearing the deletion and patients
from families with absence of the deletion.
In six NPH families there was no linkage to NPHI (Fig. 1B),
confirming the existence of at least one additional gene locus for
NPH [19]. The present study provides the basis for a historical
comparison of both groups, since progression charts (median and
quartile curves) are considered to be tools well suited to test for
heterogeneity with regards to the rate of progression to renal
failure [351.
Of note is the rapid rise in the median serum creatinine curve
once a serum creatinine of 4 mg/dl has been reached (Fig. 4B).
Furthermore, the distances between median and quartile curves
remain relatively constant, indicating that a relatively homoge-
neous group with regards to progression towards renal failure has
been analyzed.
In survival analysis there was a narrow time frame for the onset
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of terminal renal failure in NPHI, since of the 15 patients
experiencing terminal renal failure within the observation period
twelve patients reached this stage between ages 11.1 and 18.2
years. The linear shape of the survival curve in this interval seems
to reflect the action of unknown, but accurately timed genetically
determined mechanisms inducing terminal renal failure in NPHI.
Which of the so far unidentified pathogenetic mechanisms are
active before or after birth is currently unknown.
In two patients terminal renal failure occurred rather early in
comparison to the cohort. in one of them (F21 Il-i) terminal
renal failure developed as a consequence of acute renal failure on
the basis of severe dehydration. On the other hand there were two
patients with delayed progression to terminal failure: one patient
only reached a Sr of 5 mgldl at age 21 years and in another
patient a creatinine of 1.4 mgldl was measured at age 29 years.
The relatively mild clinical courses in these two patients are of
note, since they might point to a non-genetic factor, such as
environment, that might play a beneficial role in delaying the
progression to end-stage renal disease in NPHI. If present, it
would be of great interest to identify this factor, since it might
provide a means for potential therapeutic or prophylactic inter-
vention, which has been completely lacking in NPH to date.
In the present study we examined the time course of Sr
comparing the age at an S. value of 5.5 mg/dl between siblings on
the one hand and and between individuals of different families on
the other hand. The intrafamilial variability was pronounced
(patients with the deletion 6.1 5.9 years, range 0.4 to 18.4 years;
patients without the deletion 4.3 2.6 years, range 1.0 to 9.0
years). However, our data analysis revealed no significant differ-
ence in intrafamilial variability of the rate of progression between
families with (NPH1) and without the deletion (non-NPH1).
Since siblings affected by an autosomal recessive disease must
bear the same disease alleles and, in addition, being siblings, share
a large proportion of all genetic material, intrafamilial variability
might indicate the action of non-genetic influences on the devel-
opment of terminal renal failure in NPHI or, alternatively, would
point to an effect of modifier genes.
Interestingly, there was also no difference between the two
groups concerning the progression to ESRD. This finding corrob-
orates the notion that there is no clinical or histological feature
known so far that would allow a discrimination between NPH1
(deletion-positive) and non-NPH1 (deletion-negative).
in a previous study, which shows no overlap with the patients
examined in this study [34], the survival analysis revealed a
median age for terminal renal failure of 13.0 years in male
patients and of 12.8 years in female patients. The median age of
13.1 years reported in this study is in full accordance with these
data. In the previous study there was no differentiation of NPHI
versus non-NPHI.
Survival curves and median and quartile curves of Srvalues
similar to those presented in this study have been used sucessfully
to demonstrate the efficiency of cysteamine treatment against the
development of renal failure in nephropathic cystinosis [381.
These authors used published progression charts [36] overlaying
the data of the natural course with data of the treated patients.
We consider standard values for the progression toward renal
failure in NPHI to he of great interest, since the imminent
identification of the responsible gene will elicit studies on patho-
genetic aspects or even therapeutic measures that might influence
the rate of progression to renal failure in NPH1.
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